A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH MODERATE ALOPECIA AREATA

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the potential treatment of moderate alopecia areata (AA).
This study is seeking participants who are
* 12 years or older (if permitted by the local IRB/EC and local regulatory health authority)
* have AA with patchy hair loss. The current episode of hair loss has lasted for 6 months or longer but 10 years or less
* do not have any other diseases or conditions affecting hair loss.
Participants will have a 2 in 3 chance of receiving ritlecitinib 50 mg and a 1 in 3 chance of receiving placebo. The placebo looks like the study medicine but does not contain any active ingredients. Participants will not know what you have been assigned to receive. They will take ritlecitinib or placebo once daily by mouth at home for 24 weeks (6 months). After 24 weeks, the assigned treatment may stay the same or be changed to ritlecitinib 50 mg or 100 mg. This change will depend on how participants' alopecia areata responds to the treatment. Participants will receive the newly assigned treatment for another 23 weeks.
About 4 weeks after the last dose, there will be a follow-up visit. At this visit, the team will check on your health. Participants will take part in this study for about 57 weeks. During this time, they will have study visits at the study clinic. Some study checks will be done by phone.
We will compare the experiences of people receiving ritlecitinib to those of people who do not. This will help us determine if ritlecitinib is safe and effective.

Start Date31 Jul 2026

Sponsor / Collaborator

Pfizer Inc.

NCT06795373

/ WithdrawnPhase 2IIT

A Single-center, Single-arm, Open-label Phase IIA Clinical Trial to Investigate Efficacy and Safety of Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria

The purpose of this research study is to see if a drug called ritlecitinib is safe and effective for treating chronic spontaneous urticaria (CSU). CSU is hives and itching lasting over six weeks. Ritlecitinib is approved by the Food and Drug Administration (FDA) to treat another condition, but it is not approved for treating CSU. Participation is expected to last 20 weeks and include 7 clinic visits. This study will involve physical examinations, blood tests, looking at and taking pictures of participant's skin and hives, optional skin biopsies, and hearing tests. Eligible participants for this study will take ritlecitinib for 12 weeks and complete a daily diary about their skin and hives. The main risks of being in this study are side effects from ritlecitinib. Less than 1 in 10 people taking ritlecitinib experience diarrhea, acne, hives, rash, inflammation of hair follicles, dizziness, and increased blood levels of creatine phosphokinase (a muscle protein). Participants could also experience a rare but serious side effect, such as shingles, unusual infection, cancer, or blood clot. Benefits of participating in this study include a potential improvement in participant's condition and quality of life. Participating in this study may also help researchers develop new ways of helping future patients.

Start Date31 Dec 2025

Sponsor / Collaborator

Icahn School of Medicine at Mount Sinai

NCT07226531

/ Active, not recruitingNot Applicable

RETROSPECTIVE COHORT STUDY TO ASSESS UTILIZATION AND EFFECTIVENESS OF RITLECITINIB IN A REAL-WORLD POPULATION WITH SEVERE ALOPECIA AREATA IN THE UNITED STATES

Alopecia areata (AA) is a chronic, relapsing T-cell mediated autoimmune disease characterized by nonscarring, typically patchy hair loss that affects people of all ages, races, and genders. In the United States (US), AA has an estimated point prevalence of 1.14% (Beningo et al., 2020). The three most common subtypes of AA are defined by the affected area:
* Patchy alopecia (PA), as seen in 90% of clinical diagnoses: hair loss occurring in one or more patches (ranging from coin-sized to large patches and even full scalp involvement) on the scalp or other parts of the body;
* Alopecia totalis (AT): loss of all or nearly all scalp hair;
* Alopecia universalis (AU): loss of all or nearly all scalp, face, and body hair Traditionally, a range of medications, including corticosteroids, immunotherapy, and minoxidil, are used to treat AA. However, few of these mainstay therapies are supported by robust clinical evidence, limiting the development of widely accepted clinical practice guidelines (Asfour et al., 2023). As a result of suboptimal effectiveness of traditional therapies, patients with AA, particularly those with extensive hair loss, have a persistent unmet medical need. Furthermore, the potential effects of AA on other subgroups, including patients with skin of color, remain undefined. As these subgroups have been historically underrepresented in clinical trials, an additional unmet medical need and evidence gap exists for these patients.
Recent clinical studies have demonstrated efficacy of novel treatments for AA, including ritlecitinib, a JAK3/TEC family kinase inhibitor developed and marketed by Pfizer (King et al., 2023). Ritlecitinib was approved by the US Food and Drug Administration (FDA) in June 2023 for the treatment of severe AA in adults and adolescents aged 12 years or older. Extensive information from clinical trials exists on the safety and efficacy of ritlecitinib, which, along with JAK inhibitors such as baricitinib and deuruxolitinib that are FDA approved for severe alopecia areas in adults 18 and over, have presented needed new therapeutic options for these patients. However, little is known about the clinical effectiveness of ritlecitinib in real-world clinical practice.
The objective of the current study is to evaluate patient characteristics, treatment patterns and related clinical outcomes of patients who initiated ritlecitinib to treat severe AA.

Start Date22 Dec 2025

Sponsor / Collaborator

Pfizer Inc.

100 Clinical Results associated with Ritlecitinib Tosilate

100 Translational Medicine associated with Ritlecitinib Tosilate

100 Patents (Medical) associated with Ritlecitinib Tosilate

238

Literatures (Medical) associated with Ritlecitinib Tosilate

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Patient preferences for treatment characteristics of Janus kinase inhibitors for alopecia areata: a discrete choice experiment

Article

Author: Barghout, Victoria ; Mostaghimi, Arash ; Mesinkovska, Natasha ; Deering, Kathleen L. ; Harshaw, Qing ; Ferro, Thomas J.

BACKGROUND:

Janus kinase inhibitors (JAKis) can improve hair regrowth in alopecia areata (AA).

OBJECTIVE:

This study examined which treatment attributes patients value most when evaluating hypothetical JAKi-based therapies.

METHODS:

A discrete choice experiment was conducted among adults with ≥50% hair loss, recruited through the National Alopecia Areata Foundation (February-March 2024). Participants completed 10 binary choices comparing three hypothetical JAKi attributes: proportion with scalp hair regrowth, time to initial hair regrowth, and dosing frequency; safety attributes were held constant across profiles because the safety profiles were similar among JAKis approved for AA. Relative importance (RI) was calculated using preference weights. Additionally, participants ranked three blinded treatment profiles developed from phase 2b-3 data: drug profile A (baricitinib 4 mg), drug profile B (ritlecitinib 50 mg), and drug profile C (deuruxolitinib 8 mg).

RESULTS:

Among 302 patients (85% women, 81% White, mean age 43.2 years), the most valued attribute was scalp regrowth (RI = 60.0%), followed by time to initial regrowth (28.2%) and dosing frequency (11.7%). Drug profile C was most preferred (83%), and drug profile B was least preferred (85%).

CONCLUSION:

When considering efficacy only, patients prioritize higher efficacy and faster time to hair regrowth above dosing convenience in JAKi treatment preferences for AA.

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study

Article

Author: Lei, Ziyi ; Cen, Junjie ; Zhan, Jinshan ; Xu, Yantao ; Wan, Miaojian ; Tang, Xin

METHODS:

Reports associated with JAK inhibitors in AA (2015-2025) were retrieved from the FDA Adverse Event Reporting System (FAERS). Disproportionality analyses utilized within-class and external non-JAK comparisons. Additionally, time-to-onset (TTO), serious adverse event (SAE) profiles, and sensitivity analyses were assessed.

RESULTS:

Among 1,905 identified reports (baricitinib [n = 881], ritlecitinib [n = 515], tofacitinib [n = 489], ruxolitinib [n = 20]), safety signals varied across agents. Tofacitinib showed signals involving neuropsychiatric and autoimmune events; baricitinib was associated with thrombocytosis, deep vein thrombosis, and breast cancer; ruxolitinib with pyrexia and elevated blood cholesterol; and ritlecitinib with gastrointestinal events and creatine phosphokinase elevation. TTO patterns were also heterogeneous, with earlier onset for tofacitinib and ruxolitinib, clustering within the first month for ritlecitinib, and a relatively delayed onset for baricitinib. Across the class, serious outcomes were most commonly related to infections, although the distribution of clinical outcomes differed by agent.

CONCLUSIONS:

JAK inhibitors used in AA demonstrated heterogeneous post-marketing safety patterns not fully captured by class-level warnings. These findings support agent-specific surveillance and individualized risk assessment in clinical practice.

01 Aug 2026·CURRENT OPINION IN PHARMACOLOGY

Alopecia areata: Mechanisms, targeted therapies, and translational challenges

Review

Author: Kumar, Pawan ; Kumar, Virender ; Sahoo, Saurabh

Alopecia areata (AA) is an immune-mediated disorder characterized by non-scarring hair loss and substantial psychosocial burden. Although recent advances have clarified key pathogenic mechanisms and expanded therapeutic options, important uncertainties persist regarding disease heterogeneity, treatment durability, and long-term safety. Central to AA pathogenesis is the collapse of hair follicle immune privilege, driven primarily by cytotoxic CD8⁺ NKG2D⁺ T-cells and sustained by interferon-γ-dependent Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling. However, emerging evidence indicates immunological variability across patient subsets, including inconsistent contributions from T helper cell pathways and regulatory immune dysfunction. The clinical approval of JAK inhibitors-baricitinib, ritlecitinib, and deuruxolitinib-represents a major therapeutic milestone, validating targeted immune modulation as an effective strategy for moderate-to-severe AA. Nevertheless, relapse following treatment discontinuation, interindividual variability in response, and unresolved long-term safety considerations highlight the limitations of current approaches. In parallel, regenerative therapies, microbiome-based interventions, gene-targeted strategies, and device-assisted technologies are under investigation, yet most face substantial translational, regulatory, and scalability challenges. This review critically synthesizes current evidence on AA pathogenesis and therapy, with particular emphasis on unresolved controversies, translational barriers, and clinical implications. By integrating mechanistic insights with emerging clinical data, the article highlights priorities for future research, including biomarker development, precision medicine approaches, and strategies aimed at achieving durable disease control rather than transient immune suppression.

News (Medical) associated with Ritlecitinib Tosilate

30 Jul 2026

·www.fiercepharma.com

Pfizer takes Litfulo to regulators in vitiligo challenge to Incyte, AbbVie

In hopes of challenging Incyte’s topical JAK inhibitor Opzelura, Pfizer is headed to regulators with results from a pair of late-stage studies testing its would-be oral rival Litfulo in nonsegmental vitiligo (NSV). Pfizer assessed Litfulo—also known as ritlecitinib and first cleared by the FDA to treat severe alopecia areata in mid-2023—in a pair of phase 3 trials dubbed Tranquillo and Tranquillo 2, focusing on patients ages 12 and older and adults only, respectively. The company said Thursday that it enlisted participants with both active and stable NSV across a broad spectrum of disease severity. NSV is a chronic autoimmune disease that causes the immune system to attack cells that make melanin, in turn causing loss of pigment that leads to white macules and patches forming on the skin and hair over time. Pfizer noted that although vitiligo is frequently thought of as a cosmetic condition, it is nevertheless “a serious autoimmune disease that can have considerable impact on patients’ lives well beyond the physical symptoms.” As it stands, Incyte’s Opzelura—applied to the body as a cream—is the only drug approved by the FDA to treat NSV. Pfizer is arguing that patients with NSV could benefit from a new systemic therapy to tackle their autoimmune condition. Moreover, there are some patients “for whom disease burden warrants more than localized treatment alone,” Iltefat Hamzavi, M.D., a senior staff physician in the dermatology department at Henry Ford Health and Hamzavi Dermatology Specialists, said in Pfizer’s release. According to topline results from the Tranquillo trials, both a 50 mg and 100 mg dose of Litfulo charted statistically significant improvements over placebo on co-primary endpoints tied to the facial and total body Vitiligo Area Scoring Index (VASI), a clinician-reported tool to assess vitiligo severity and treatment response. Pfizer noted that in both trials, “significantly more patients” who received Litfulo achieved a 75% or greater improvement on the facial scoring index (F-VASI75) and a 50% or greater improvement on the total vitiligo scoring index (T-VASI50) at the one-year mark versus placebo. The company noted that its co-primary endpoints in the U.S. are the proportion of patients with F-VASI75 and the proportion of patients with T-VASI50 at 52 weeks, while in countries outside the U.S., F-VASI75 is the sole primary endpoint. Litfulo’s safety and tolerability were on par with its reputation in alopecia areata, Pfizer said, adding that the proportion of patients with treatment-emergent adverse events was similar across cohorts. Litfulo, in its approved form, carries warnings about its potential to lower the immune system’s ability to fight infections, cause cancers, and lead to potential heart issues and blood clots, none of which are uncommon for the JAK inhibitor class at large. With positive results in hand, Pfizer said it now plans to submit regulatory filings around the world in vitiligo, with the aim to target an approval in adults. The New York pharma also intends to share additional data from the two studies at an upcoming medical meeting. As for Opzelura, the topical drug received a tailwind recently following a settlement with the Centers for Medicare & Medicaid Services on how the drug was classified in determining its rebate. With that issue resolved, Incyte earlier this week raised its full-year 2026 sales guidance for Opzelura from below $800 million to a blockbuster range of $1.05 billion to $1.1 billion. Meanwhile, another challenger could be close at hand in AbbVie’s JAK med Rinvoq, which on Wednesday picked up dual approvals in the European Union to treat both alopecia areata and NSV . Stateside, AbbVie submitted Rinvoq for FDA review in vitiligo back in early February.

30 Jul 2026

·www.pharmaindustrial-india.com

Pfizer Reports Positive Phase 3 Results for LITFULO in Vitiligo

Pfizer has announced positive topline results from 2 phase 3 trials evaluating the efficacy and safety of LITFULO once daily in patients with both active and stable nonsegmental vitiligo (NSV) and who had a broad range of disease severity. The TRANQUILLO study included patients aged 12 years and older, while TRANQUILLO 2 enrolled adults only. Across the studies, both the 50 and 100 milligram doses of LITFULO delivered significant, clinically meaningful improvements over placebo on co-primary endpoints for the facial and total body Vitiligo Area Scoring Index (VASI). Based on these results, the company intends to submit global regulatory filings for LITFULO as a potential new oral systemic therapy for NSV for adults. Michael Vincent, MD, PhD, Chief Inflammation and Immunology Officer, Pfizer, said, “LITFULO was internally discovered by Pfizer and has a unique mechanism of action targeting TEC family kinases and JAK3, giving rise to its distinct clinical profile. The positive results from the TRANQUILLO pivotal studies in nonsegmental vitiligo build on our deep expertise in dermatology and on our experience with LITFULO in severe alopecia areata, including its established efficacy and well-characterised safety profile. These findings give us confidence that, if approved, LITFULO could become a new oral systemic treatment option for adults living with NSV, significantly improving and potentially maintaining facial and total body repigmentation.” NSV is a chronic autoimmune disease in which the immune system attacks melanin-producing cells, leading to a loss of pigment and resulting in white macules and patches on the skin/hair over time. NSV can appear at any age and in all skin types, causing depigmentation anywhere on the skin, often affecting highly visible areas such as the face, neck, and hands. While vitiligo is frequently treated as a cosmetic condition, it is a serious autoimmune disease that can have a considerable impact on patients’ lives well beyond the physical symptoms. Since NSV is a chronic disease, systemic treatment options may be needed to help patients restore skin pigmentation and maintain repigmentation over time. Across both studies, significantly more patients treated with LITFULO achieved F-VASI75 (≥75 percent improvement in Facial Vitiligo Area Scoring Index) and T-VASI50 (≥50 percent improvement in Total Vitiligo Area Scoring Index) from baseline at Week 52 compared with placebo. In the US, the co-primary endpoints were the proportion of patients with F-VASI75 and the proportion of patients with T-VASI50 at Week 52. In countries outside of the US, F-VASI75 at Week 52 was the primary endpoint and T-VASI50 at Week 52 was a key secondary endpoint. The safety profile of LITFULO in NSV was consistent with the established safety profile in alopecia areata. No new safety signals were observed. Overall, the proportion of patients with Treatment?Emergent Adverse Events (TEAEs) was similar across all treatment groups. Iltefat Hamzavi, MD, Senior Staff Physician, Department of Dermatology, Henry Ford Health and Hamzavi Dermatology Specialists, said, “Living with nonsegmental vitiligo can have a profound impact on patients’ daily lives. Many patients experience frustration due to the unpredictable nature of nonsegmental vitiligo as well as the limitations of currently available treatments and are seeking additional options that can address the underlying disease. In these trials, LITFULO (ritlecitinib) demonstrated significant improvements in both facial and total body repigmentation, with the findings reinforcing the potential of LITFULO to help support a new treatment paradigm with systemic therapies for patients for whom disease burden warrants more than localised treatment alone.” Additional results from TRANQUILLO and TRANQUILLO 2 will be presented at a future medical meeting. LITFULO was approved in 2023 by the US Food and Drug Administration (FDA) for the treatment of severe alopecia areata in adults and adolescents aged12 years and older. Pfizer plans to initiate a pivotal study evaluating LITFULO for the treatment of moderate alopecia areata in 2026.

30 Jul 2026

·firstwordpharma.com

Vitiligo filings on deck after Pfizer's Litfulo succeeds in Phase III

Pfizer said Thursday that it will be seeking a label expansion for Litfulo (ritlecitinib) after two Phase III studies in patients with nonsegmental vitiligo (NSV) showed the drug led to significant repigmentation across both their face and body.Based on the results, the company is now gearing up to submit global regulatory filings to expand Litfulo's label to include adults with NSV. The drug has been approved for severe alopecia areata in the US and EU since 2023."Litfulo…has a unique mechanism of action targeting TEC family kinases and JAK3, giving rise to its distinct clinical profile," said Michael Vincent, Pfizer's chief inflammation and immunology officer. "Positive results from the TRANQUILLO pivotal studies in nonsegmental vitiligo build on…our experience with Litfulo in severe alopecia areata, including its established efficacy and well-characterised safety profile… If approved, [it] could become a new oral systemic treatment option."The TRANQUILLO study evaluated a 50-mg once-daily dose of Litfulo in 607 adults and adolescents ages 12 years and older, while TRANQUILLO 2 tested a 50-mg or 100-mg once-daily dose in 1567 adults.According to Pfizer, they each met their co-primary endpoints, with both the 50-mg and 100-mg doses producing clinically meaningful improvements over placebo in facial and total body Vitiligo Area Scoring Index (VASI) scores at the 52-week mark.Specifically, significantly more patients on Litfulo achieved at least 75% improvement in facial repigmentation (F-VASI75) and at least 50% improvement in total body repigmentation (T-VASI50) from baseline than those on placebo. In the US, both of these results were considered main measures of success for the trials; elsewhere, facial improvement was the main measure, with body improvement a key secondary one.Pfizer said the safety profile was consistent with that previously observed in alopecia areata, with no new safety signals identified and similar rates of treatment-emergent adverse events across study groups. Additional results will be presented at a future medical meeting.The vitiligo space has also seen some positive early-stage study readouts recently from Teva and Forte Biosciences (see – KOL Views Q&A: Anti-IL-15 therapies from Forte, Teva have game-changing potential in vitiligo).

Clinical ResultPhase 3Drug Approval

100 Deals associated with Ritlecitinib Tosilate

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14924

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Alopecia Areata	United States	Pfizer Inc.	23 Jun 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Nonsegmental vitiligo	Phase 3	United States	Pfizer Inc.	01 Dec 2022
Nonsegmental vitiligo	Phase 3	China	Pfizer Inc.	01 Dec 2022
Nonsegmental vitiligo	Phase 3	Japan	Pfizer Inc.	01 Dec 2022
Nonsegmental vitiligo	Phase 3	Australia	Pfizer Inc.	01 Dec 2022
Nonsegmental vitiligo	Phase 3	Bulgaria	Pfizer Inc.	01 Dec 2022
Nonsegmental vitiligo	Phase 3	Canada	Pfizer Inc.	01 Dec 2022
Nonsegmental vitiligo	Phase 3	Germany	Pfizer Inc.	01 Dec 2022
Nonsegmental vitiligo	Phase 3	India	Pfizer Inc.	01 Dec 2022
Nonsegmental vitiligo	Phase 3	Italy	Pfizer Inc.	01 Dec 2022
Nonsegmental vitiligo	Phase 3	Mexico	Pfizer Inc.	01 Dec 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05583526 \| NCT06163326 \| NCT06072183 (Tranquillo, Pubmed \| Dermatol Ther (Heidelb))	Phase 3	Nonsegmental vitiligo	1,990	Ritlecitinib 100 mg	kqjaeaunyy(djvxktpdwr) = iserfhomus htjhgttnsc (nznedjmzey ) View more	Positive	22 May 2026
	Phase 3	Nonsegmental vitiligo	1,990	Placebo	sopaldhvuu(zjsdtadgmq) = tttkjaoiwp vlexwpjxjk (migjmwvavk )	Positive	22 May 2026
NCT03732807 (ALLEGRO-2b/3, AAD2026)	Phase 2/3	Alopecia Areata	300	Ritlecitinib 50 mg	rrkcivvlvk(zgjjvdjhdj) = sgpiqnjrzc njhqchzvkc (tienxbcidg ) View more	Positive	27 Mar 2026
NCT03732807 (ALLEGRO-2b/3, AAD2026)	Phase 2	Alopecia Areata	27	Ritlecitinib 50 mg	gamdmczqdn(wmvdvcsoxu) = kcckqqismx hcmpozkevv (siwnzvlbfr ) View more	Positive	27 Mar 2026
AAD2026	Not Applicable	Alopecia Areata	129	Tofacitinib	jasveihnuj(flicxsncpy) = zoreqmratz cifhzcjznd (njsqfdzzlf ) View more	Negative	27 Mar 2026
AAD2026	Not Applicable	Alopecia Areata	129	Baricitinib	uqeqkzywak(hzvvwsuwez) = kmxatrbbvc sqblchkrlv (ztoxllhupr )	Negative	27 Mar 2026
AAD2026	Not Applicable	Alopecia Areata	32	Ritlecitinib 50mg	mwoufwrada(hyljsmcspd) = slckxiedmj csexrgjlkz (ijkphftcxu ) View more	Positive	27 Mar 2026
AAD2026	Not Applicable	Alopecia Universalis	329	Tofacitinib	mgfzlzeepd(kxjvgkzaah) = Tofacitinib was associated with shingles, acneiform eruptions, infections, gastrointestinal symptoms, weight gain, and one case of multiple sclerosis. Ruxolitinib caused mild cytopenias and gastrointestinal issues; upadacitinib led to hair depigmentation; filgotinib caused acneiform eruptions. Safety data for ritlecitinib, abrocitinib, and deuruxolitinib were limited. xadnyznziw (tezehsabsa )	Positive	27 Mar 2026
NCT03732807 (ALLEGRO, Pubmed \| Value Health)	Phase 2/3	Alopecia Areata	201	Ritlecitinib 50 mg once daily	kgufhgkvya(poetpgplfk) = beqsjxkrzq jpajuyucce (wacgcovozx ) View more	Positive	01 Feb 2026
NCT04006457 (ALLEGRO \| ALLEGRO-LT, CTgov)	Phase 3	Alopecia Areata	1,057	Ritlecitinib (Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants))	yqsgjdfttc = swehvyydop uldjymkkvb (juaochqcab, evqcsvnuzx - hkrayqskqt) View more	-	14 Aug 2025
NCT04006457 (ALLEGRO \| ALLEGRO-LT, CTgov)	Phase 3	Alopecia Areata	1,057	Ritlecitinib (Main Study: Ritlecitinib 50 mg QD (Roll-over Participants))	yqsgjdfttc = evftmtbzzv uldjymkkvb (juaochqcab, vfepmvrtsa - nbwbcdciap) View more	-	14 Aug 2025
NCT03732807 \| NCT04006457 (ALLEGRO, Pubmed \| J Eur Acad Dermatol Venereol)	Phase 2/3	Alopecia Areata	191	Ritlecitinib 50 mg	ckvrgpdrrk(dmsfhrzpyq) = xvynnsdegh wsdffwwvew (zfigimcxca ) View more	Positive	01 Jun 2025
NCT04006457 (ALLEGRO-LT, Pubmed \| J Eur Acad Dermatol Venereol)	Phase 3	Alopecia Areata	449	Ritlecitinib 200mg loading dose followed by 50mg daily	egnjtbdlyf(wkkhcwqltl) = occurred in six patients pnjmjrqguc (kgaylmmbnm ) View more	Positive	01 Jun 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis